Treatment advice of small molecule antiviral drugs for elderly COVID-19 / 中国药理学通报
Chinese Pharmacological Bulletin
; (12): 425-430, 2023.
Article
de Zh
| WPRIM
| ID: wpr-1013933
Bibliothèque responsable:
WPRO
ABSTRACT
COVID-19 has been prevalent for three years. The virulence of SARS-CoV-2 is weaken as it mutates continuously. However, elderly patients, especially those with underlying diseases, are still at high risk of developing severe infections. With the continuous study of the molecular structure and pathogenic mechanism of SARS-CoV-2, antiviral drugs for COVID-19 have been successively marketed, and these anti-SARS-CoV-2 drugs can effectively reduce the severe rate and mortality of elderly patients. This article reviews the mechanism, clinical medication regimens, drug interactions and adverse reactions of five small molecule antiviral drugs currently approved for marketing in China, so as to provide advice for the clinical rational use of anti-SARS-CoV-2 in the elderly.
Texte intégral:
1
Base de données:
WPRIM
Langue:
Zh
Journal:
Chinese Pharmacological Bulletin
Année:
2023
Type de document:
Article